Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDesbois, Andrew Pen_UK
dc.contributor.authorGemmell, Curtis Gen_UK
dc.contributor.authorCoote, Peter Jen_UK
dc.description.abstractNew treatments are urgently required for infections caused by meticillin-resistant Staphylococcus aureus (MRSA) as these strains are often resistant to multiple conventional antibiotics. Earlier studies showed that ranalexin, an antimicrobial peptide (AMP), in combination with lysostaphin, an antistaphylococcal endopeptidase, synergistically inhibits the growth of MRSA, meaning that it deserved consideration as a new anti-S. aureus therapy. Using haemolysis and Vero cell viability assays, ranalexin with lysostaphin is proven to be non-toxic at antibacterial concentrations. In human serum, ranalexin with lysostaphin is significantly more effective against MRSA than treatment with either component alone. In a rabbit model of wound infection, ranalexin with lysostaphin reduced MRSA in the wound by ca. 3.5 log10 colony-forming units (CFU) compared with the untreated control. The combination is significantly more effective than treatment with ranalexin or lysostaphin alone. In a mouse model of systemic infection, ranalexin with lysostaphin reduced MRSA kidney burden by ca. 1 log10 CFU/g compared with untreated controls or treatment with ranalexin or lysostaphin alone. Importantly, the combination is synergistically bactericidal against various S. aureus isolates in vitro, including those with reduced susceptibility to lysostaphin or vancomycin. Ranalexin and lysostaphin could be incorporated in wound dressings for the prevention and treatment of topical S. aureus infections. That AMPs can enhance the antibacterial effectiveness of lysostaphin in vivo highlights a new avenue of research in the fight against drug-resistant staphylococci.en_UK
dc.relationDesbois AP, Gemmell CG & Coote PJ (2010) In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections. International Journal of Antimicrobial Agents, 35 (6), pp. 559-565.;
dc.rightsThe publisher does not allow this work to be made publicly available in this Repository. Please use the Request a Copy feature at the foot of the Repository record to request a copy directly from the author. You can only request a copy if you wish to use this work for your own research or private study.en_UK
dc.subjectAntibiotic resistanceen_UK
dc.subjectKidney burdenen_UK
dc.subjectStaphylococcus aureusen_UK
dc.titleIn vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infectionsen_UK
dc.typeJournal Articleen_UK
dc.rights.embargoreason[desboisgemmellcoote_intljantimicrobagents_2010.pdf] The publisher does not allow this work to be made publicly available in this Repository therefore there is an embargo on the full text of the work.en_UK
dc.citation.jtitleInternational Journal of Antimicrobial Agentsen_UK
dc.type.statusVoR - Version of Recorden_UK
dc.contributor.affiliationInstitute of Aquacultureen_UK
dc.contributor.affiliationUniversity of St Andrewsen_UK
dc.contributor.affiliationUniversity of St Andrewsen_UK
rioxxterms.typeJournal Article/Reviewen_UK
local.rioxx.authorDesbois, Andrew P|0000-0001-6052-8761en_UK
local.rioxx.authorGemmell, Curtis G|en_UK
local.rioxx.authorCoote, Peter J|en_UK
local.rioxx.projectInternal Project|University of Stirling|
Appears in Collections:Aquaculture Journal Articles

Files in This Item:
File Description SizeFormat 
desboisgemmellcoote_intljantimicrobagents_2010.pdfFulltext - Published Version290.89 kBAdobe PDFUnder Permanent Embargo    Request a copy

This item is protected by original copyright

Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved

If you believe that any material held in STORRE infringes copyright, please contact providing details and we will remove the Work from public display in STORRE and investigate your claim.